| Raymond F. Anton, M.D. Distinguished Professor |
 |
|||||
| Charleston Alcohol Research Center Roles: | ||||||
|
||||||
| Raymond F. Anton, M.D. Distinguished Professor |
|
|||||
| Charleston Alcohol Research Center Roles: | ||||||
|
||||||
Education
| Institution | Degree | Year | Field |
|
Rutgers University, New Brunswick, NJ
|
B.A. | 1972 | Biosciences |
| Rutgers School of Medicine, New Brunswick, NJ | M.D. | 1976 | Medicine |
| Greenwich Hospital, Greenwich, CT | Internship | 1977 | Medicine |
| Yale New Haven Hospital & Connecticut Mental Health Center, New Haven, CT | Residency |
|
Psychiatry |
| Yale University School of Medicine, New Haven, CT | Postdoctoral | 1980 | Psychiatry |
Professional Experience
|
Year
|
Position |
| 1980-1985 | Assistant Professor, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina (MUSC), Charleston, SC |
| 1980-1988 | Staff Psychiatrist, Veterans Administration Medical Center, Charleston, SC |
| 1984-1988 | Director, Psychopharmacology Research, Veterans Admin. Medical Center, Charleston, SC |
| 1985-1991 | Associate Professor, Department of Psychiatry and Behavioral Sciences, MUSC, Charleston, SC |
| 1988-Present | Director, Clinical-Neurobiology Laboratories, Department of Psychiatry and Behavioral Sciences, MUSC, Charleston, SC |
| 1991-Present | Professor, Department of Psychiatry and Behavioral Sciences, MUSC, Charleston, SC |
| 1993-Present | Director, Alcohol Medication Studies, Center for Drug and Alcohol Programs, MUSC, Charleston, SC |
| 1995-Present | Scientific Director for Clinical Research, Alcohol Research Center, MUSC, Charleston, SC |
| 1998-Present | Director of Research, Center for Drug and Alcohol Programs, MUSC, Charleston, SC |
| 2001-Present | Director, Center for Drug & Alcohol Programs |
| 2002-Present | Distinguished University Professor, Dept. of Psychiatry & Behavioral Sciences, MUSC, Charleston, SC |
Awards/Honors
|
Year
|
Award/Honor |
| 1991 | NIAAA Alcohol Psychosocial Research Review Committee (Member Clinical & Treatment Subcommittee; Chair, 1993-1994) |
| 1992 | NIAAA Working Group on Methodology in Clinical Treatment Research Trials |
| 1992 | NIAAA Task Force on Revision of the Treatment Assessment Manual |
| 1996 | American College of Neuropsychopharmacology (elected member) |
| 1997 | American Society of Addiction Medicine (diplomat) |
| 1997 | Added Qualifications in Addiction Psychiatry |
| 1999-Present | Board of Scientific Counselors of the National Institute of Alcohol Abuse and Alcoholism |
| 1999 | Board of Directors, Research Society on Alcoholism |
| 2000 | Member, Board of Reviewing Editors, Alcoholism: Clinical and Experimental Research |
| 2000-Present | Chairman, Steering Committee, COMBINE Study |
| 2001 | Treasurer, Research Society on Alcoholism |
| 2003 | Fellowship, American College of Neuropsychopharmacology |
| 2005 | Vice-Chairman, Board of Trustees, Alcohol Beverage Medical Research Foundation |
| 2006 | President-elect, Research Society on Alcoholism |
| 2007 | President, Research Society on Alcoholism |
Representative Publications
Baros AM, Latham PK, Moak DH, Voronin K & Anton RF. What role does measuring medication compliance play in evaluating the efficacy of naltrexone? Alcoholism: Clinical & Experimental Research 31(4):596-603, 2007.
Cluver JS, Miller PM & Anton RF. Case studies of the utility of serum carbohydrate-deficient transferrin (%CDT) in the clinical management of alcoholics. Journal of Addiction Medicine 1(1):44-47, 2007.
Jeppsson J-O, Arndt T, Schellenberg F, Wielders JPM, Anton RF, Whitfield JB, Helander A & International Federation of Clinical Chemistry and Laboratory Medicine Working Group on Standardization of Carbohydrate-Deficient Transferin. Toward standardization of carbohydrate-deficient transferrin (CDT) measurements: I. Analyte definition and proposal of a candidate reference method. Clinical Chemistry & Laboratory Medicine 45(4):558-562, 2007.
Myrick H, Anton RF, Voronin K, Wang W & Henderson S. A double blind evaluation of gabapentin on alcohol effects and drinking in a clinical laboratory paradigm. Alcoholism: Clinical & Experimental Research 31(2):221-227, 2007.
Work Group on Substance Use Disorders (Anton RF). Practice guideline for the treatment of patients with substance use disorders. Supplement to American Journal of Psychiatry 164(4):A5-124, 2007.
Wright TM, Baros AM & Anton RF. Pharmacotherapies for the Treatment of Alcohol Dependence: Current and on the Horizon In Translation of Addictions Science into Practice: Update and Future Directions, Miller PM, Kavanagh D (Eds). Elsevier-Pergamon, New York, NY, 2007.
Wright TM, Myrick H, Malcolm R, Randall P, Boyle E, Henderson S & Anton R. Impact of lifetime alcohol quit attempts and medicated detoxifications on time to relapse during an index alcohol detoxification. Journal of Addiction Medicine 1(1):15-20, 2007.